NASDAQ:MRUS - Merus Stock Price, Forecast & News

Merus trades on the NASDAQ under the ticker symbol "MRUS."

Merus is scheduled to release their next quarterly earnings announcement on Wednesday, April 1st 2020. View Earnings Estimates for Merus.

6 brokers have issued 1-year price targets for Merus' shares. Their forecasts range from $16.00 to $35.00. On average, they anticipate Merus' share price to reach $24.00 in the next twelve months. This suggests a possible upside of 43.4% from the stock's current price. View Analyst Price Targets for Merus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merus in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Merus.

Headlines about MRUS stock have been trending extremely negative on Friday, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Merus earned a daily sentiment score of -4.4 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Merus.

Merus saw a decrease in short interest in the month of February. As of February 14th, there was short interest totalling 368,500 shares, a decrease of 15.6% from the January 30th total of 436,600 shares. Based on an average trading volume of 76,600 shares, the short-interest ratio is currently 4.8 days. Approximately 2.0% of the company's shares are sold short. View Merus' Current Options Chain.

Some companies that are related to Merus include Alder Biopharmaceuticals (ALDR), Esperion Therapeutics (ESPR), Corcept Therapeutics (CORT), Aimmune Therapeutics (AIMT), Endo International (ENDP), Constellation Pharmaceuticals (CNST), Dicerna Pharmaceuticals (DRNA), Innoviva (INVA), TG Therapeutics (TGTX), Theravance Biopharma (TBPH), Madrigal Pharmaceuticals (MDGL), Nabriva Therapeutics (NBRV), ZEALAND PHARMA/S (ZEAL), Y-mAbs Therapeutics (YMAB) and Zogenix (ZGNX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Merus investors own include AbbVie (ABBV), Enterprise Products Partners (EPD), Exelixis (EXEL), ImmunoGen (IMGN), Viking Therapeutics (VKTX), AT&T (T), Corbus Pharmaceuticals (CRBP), Fate Therapeutics (FATE), GlycoMimetics (GLYC) and Idera Pharmaceuticals (IDRA).

(MRUS) raised $64 million in an initial public offering (IPO) on Thursday, May 19th 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers.

Merus' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BVF Inc. IL (13.54%), EcoR1 Capital LLC (7.34%), Driehaus Capital Management LLC (6.13%), Platinum Investment Management Ltd. (0.73%), Oxford Asset Management LLP (0.22%) and Old West Investment Management LLC (0.11%). Company insiders that own Merus stock include Bvf Partners L P/Il, Mark Throsby and Value Fund L P Biotechnology. View Institutional Ownership Trends for Merus.

MRUS stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL and Tower Research Capital LLC TRC . View Insider Buying and Selling for Merus.

MRUS stock was acquired by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, Driehaus Capital Management LLC, Oxford Asset Management LLP, Platinum Investment Management Ltd., Old West Investment Management LLC, Renaissance Technologies LLC, Marshall Wace LLP and Acadian Asset Management LLC. Company insiders that have bought Merus stock in the last two years include Bvf Partners L P/Il and Value Fund L P Biotechnology. View Insider Buying and Selling for Merus.

Shares of MRUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MRUS stock can currently be purchased for approximately $16.74.

Merus has a market capitalization of $391.88 million and generates $37.14 million in revenue each year. The biotechnology company earns $-28,660,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis. Merus employs 98 workers across the globe.View Additional Information About Merus.

The official website for Merus is http://www.merus.nl/.

Merus' mailing address is YALELAAN 62, UTRECHT P7, 3584 CM. The biotechnology company can be reached via phone at 31-0-30-253-8800 or via email at [email protected]